Paul Thomas Email & Phone Number

San Diego, California, Us

Prominex was founded in 2018 by experienced diagnostics industry executives with a goal to develop Molecular Point-of-Care Testing (MDx POCT) solutions for infectious diseases. The patent-protected amplification chemistry and detection technologies utilized in our Prominex System enables the delivery of accurate sample-to-answer test results in less than 5 minutes. Our assay development activities are currently focused on SARS-CoV-2 in response to the Covid-19 pandemic.

Deerfield, Illinois, Us

Alachua, Fl, Us

Lake Forest Park, Washington, Us

Lake Forest Park, Washington, Us

Roka Bioscience is a leader in molecular diagnostics technologies and automated instrument platforms for industrial applications. The Company develops and markets innovative molecular assays that provide fast, accurate and cost-effective microbiological testing solutions.Led the spinout of Gen-Probe’s (NASDAQ:GPRO) technology assets into a new independent company with financial sponsorship from leading private equity firms Orbimed Advisors, New Enterprise Associates, TPG Biotech and Aisling Capital.• Completed successful IPO raising $60M in July 2014.

San Antonio, Tx, Us

LifeCell is a leader in the emerging field of regenerative medicine. The Company develops and markets a portfolio of innovative tissue repair products for use in reconstructive, orthopedic and urgynecologic surgical procedures.• Led the transition of LifeCell from a research entity to a company focused on the profitable commercialization of innovative reconstructive tissue matrix products. Successfully sold LifeCell to Kinetic Concepts, Inc. in a 100% cash transaction for $1.8 billion in May 2008. The transaction multiples were 9.05x TTM revenue, 35.8x TTM EBITDA and 48.6x 2008E EPS Completed a major restructuring of the strategic direction, management team and physical infrastructure of the company to provide the foundation for future growth. Annual product revenues increased from $7.2 million in 1998 to $190 million in 2007 while the market capitalization of the Company grew from less than $50 million to $1.8 billion in the same period. Established a direct hospital-based sales force (~87 representatives) for the marketing of AlloDerm & Strattice in reconstructive surgery. Established significant distribution partnerships with Boston Scientific (Repliform 1999); Wright Medical (GraftJacket 2002); Stryker Orthopedics (AlloCraft DBM 2003) and Tornier (Conexa 2008). Completed several PIPE transactions totaling $35 million

Ohmeda is a world leader in anesthesia and critical care products (pharmaceuticals, medical equipment and medical devices) with global sales of approximately $800 million. The Pharmaceutical Produces Division (PPD) of Ohmeda is a leading provider of inhalation anesthetics and acute care pharmaceuticals used in the OR/ICU areas of the hospital.• Transformed the pharmaceutical business to a more broadly based provider of novel therapeutics and complementary generic injectables. Initiated major Phase II/III clinical trials program for inhaled nitric oxide (NO: Molecule of the Year, Science, 1992) for the treatment of persistent pulmonary hypertension of the newborn (PPHN) and acute respiratory distress syndrome (ARDS). Secured board approval to invest approximately $60 million in this promising therapy.

 Received board approval for Suprane development, including a $96 million plant expansion. Directed Suprane market launch to maintain overall leadership position for inhaled anesthetics. Achieved first full year Suprane sales of approximately $40 million and a 20% market share. Championed the $36 million acquisition of Delta Biotechnology, a U.K. based leader in the development of recombinant human albumin. Successfully negotiated the $73 million acquisition of Brevibloc®, an ultra-short-acting ß blocker, from DuPont Merck. Repositioned and relaunched Brevibloc® which resulted in 12% per annum sales growth from a static base. Licensed the North American marketing rights for inhaled nitric oxide from the Massachusetts General Hospital.

Mba – Marketing/Finance

Research/Teaching Fellow In Chemistry

A.B. Cum Laude – Chemistry